3. Olansky has received honoraria from Amylin/Lilly and Merck for teaching and speaking.
4. Olansky reassured us in 2010 that data for the period from June 2005 to June 2008 suggested the chances of developing pancreatitis from the incretin-based therapies (exenatide and sitagliptin) was no greater than that associated with metformin or glyburide.
5. Butler and his colleagues revealed in 2011 that data from 2004 to 2009 suggested the chances of developing pancreatitis from the incretin-based therapies (exenatide and sitagliptin) was SIX-FOLD that associated with four other therapies selected as control drugs (rosiglitazone, nateglinide, repaglinide and glipizide).
I feel sure that by posting conclusions based upon outdated information of an individual whose impartiality was questionable, in an attempt to deceive us regarding the risks now associated with exenatide therapy, Tsarma did not mean you any harm. He was doubtless focussed solely upon personal financial gain.
Just business - nothing personal.
Btw - for anybody curious to know where all these drugs fit into the diabetes therapy picture there's a useful wikipedia chart -
Financial motives are fair enough. All of us posting here have financial motives pro and con. I highly doubt anyone comes to the YMB for medical advice. It's purely for investment purposes and whether you believe Amylin is a worthwhile place for your money. You clearly don't think it is and quote the same study over and over again under the guise of being impartial. Quoting ONE study with significant methodologic FLAWS (see link below for details if you are REALLY interested) shows intellectual DISHONESTY.
I'll admit that I don't know if GLP-1s cause pancreatitis. But the data so far argues against an association. The FDA overreacted in 2008 after its highly publicized Avandia (rosiglitazone) debacle. The only way to know for sure is to analyze randomized controlled trials which so far don't show any link. The downside to this is that these trials are small in number so may miss rare events that could be potentially seen in a larger population. But these studies don't show a link:
"I'll admit that I don't know if GLP-1s cause pancreatitis. But the data so far argues against an association."
Butler and his colleagues were clearly of a different opinion.
And as for your -
"Quoting ONE study with significant methodologic FLAWS (see link below for details if you are REALLY interested)"
- given that it's the most RECENT study I've seen, and that it covered Adverse Event Reports over such a long period, it seems to me to be far and away the most relevant study to quote.
As far as I am aware, the alleged "flaws" in the study have not been alleged by anybody who didn't have a financial interest in either Byetta/Bydureon or Januvia/Janumet.
If you personally are convinced that the study was flawed - why don't you simply offer your reasoning to us? I'm certain that the majority of the users of this forum would be interested in your take on this.
Btw - my motivation for being here has never at any stage been financial. It was initially solely about teaching Terry a lesson. Other pumpers here had the bright idea of trying to annoy me, and succeeded. And here we are.